|CERVIX||Female Genital Tract and Breast||Squamous tumours and precursors||MALIGNANT||non keratinising squmaous cell carcinoma|
|Cancer Incidence||Currently 1 million cases of SIL detected per year in US, 13,000 new invasive carcinomas)|
|Cancer Genetic||Tp 53, c erb, c myc Tp 53, c erb, c myc|
|Cancer Cytopathological Finding||Malignant squamous cells.|
|Cancer Histopathological Finding||Composed of generally recognizable polygonal squamous cells that may have individual cell keratinization and intercellular bridges, but keratin pearls are absent.|
The most common chemotherapy combinations used to treat cervical cancer are:
If cervical cancer does not respond to drugs used in earlier treatments or if it recurs, other drugs that may be used are:
The most common drug combinations used to treat recurrent or metastatic cervical cancer are:
pelvic radiotherapy to a dose of 50 Gy/25 fraction/5 weeks by four field
box technique followed by high-dose-rate brachytherapy (3 sessions, each of 7.5 Gy to point A).
|Cancer Definitive Medicine||The most common chemotherapy combinations used to treat cervical cancer are: carboplatin (Paraplatin) and docetaxel (Taxotere) carboplatin and paclitaxel (Taxol) cisplatin and etoposide(Vepesid, VP-16) used to treat small cell carcinoma of the cervix If cervical cancer does not respond to drugs used in earlier treatments or if it recurs, other drugs that may be used are: paclitaxel topotecan (Hycamtin) gemcitabine (Gemzar) The most common drug combinations used to treat recurrent or metastatic cervical cancer are: cisplatin and topotecan carboplatin and paclitaxel paclitaxel and cisplatin cisplatin and gemcitabine|
|Cancer Diet||Low fat, high calorie, high protein diet with lot of vegetables & fruits get vaccinated AVOIDED - Smoking, overweight, long –term use of oral contraceptives.|
|Cancer Stages Master||
FIGO/UICC staging – cervical cancer
*FIGO no longer includes stage 0 (Tis)
WITH SLIGHT VARIATION ON THE BASIS OF AGE , RACE, SOCIOECONOMIC STATUS 5YEAR CAUSE SPECIFIC SURVIVAL RATE FOR STAGE IIOF 61%-66%,STAGE II 47% AND FOR STAGE III38%.